Sat.Nov 25, 2023 - Fri.Dec 01, 2023

article thumbnail

Clinical Trial Labeling: Don’t Get Stuck

Imperical Blog

Clinical trial labeling is complex. Discover how Imperial CRS helped a client overcome some of the complexities of this critical clinical trial component. Did you know that product labels are big business? Labels are a lively commercial niche, and the global market for pharmaceutical labels… The post Clinical Trial Labeling: Don’t Get Stuck appeared first on Imperial Clinical Research Services Blog.

article thumbnail

Cultivating quality excellence in the clinical trials landscape

pharmaphorum

Cultivating quality excellence in the clinical trials landscape Mike.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

IRT for clinical trials: Key features to look for

Antidote

Interactive Response Technology (IRT) is an umbrella term that includes Interactive Web Response (IWRS) and Interactive Voice Response (IVRS) systems. These tools serve a critical role in ensuring clinical trials run smoothly, and as technologies develop, their capabilities only continue to expand.

article thumbnail

How to Enable Patient-Centric Co-Design for Better Healthcare Solutions

XTalks

Patient-centric co-design refers to an approach where patients or end-users are actively involved with healthcare professionals, designers and other stakeholders to develop healthcare services or products. It allows for the creation of more effective, accessible and user-friendly healthcare solutions that align with the actual needs and desires of patients.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Putting patients at the centre of innovation starts with clinical trial access

pharmaphorum

Putting patients at the centre of innovation starts with clinical trial access Mike.

article thumbnail

Interview: Issues in data-monitoring for complex clinical trials

Outsourcing Pharma

Professor Deborah Ashby, interim Dean of the Faculty of Medicine, Imperial College, delivered this yearâs Sally Hollis Memorial Lecture. OSP enjoyed a discussion with both her and Professor Jennifer Visser-Rogers, vice-president for statistical research and consultancy at Phastar, about how new approaches to clinical trials are changing data monitoring committees.

More Trending

article thumbnail

Amplifying Patient Voices in Breast Cancer Clinical Trials

XTalks

In this discussion with Dr. David Cameron, Chair of the Breast International Group (BIG) , we delve into the landscape of breast cancer research today, clinical trials and the incorporation of the patient voice in breast cancer research. With a vast repository of knowledge and expertise in international clinical trials, Dr. Cameron’s insights offer a valuable understanding of where we stand in breast cancer research today.

article thumbnail

‘What If?’ Poetry as a platform for the patient voice

pharmaphorum

Held at London’s Battersea Arts Centre on 5th October, Sanofi’s ‘What If?’ People’s Poem event coincided with National Poetry Day.

59
article thumbnail

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

Bio Pharma Dive

U.S. tax law changes enacted six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

article thumbnail

Japan grants approval for CSL and Arcturus’ Covid-19 vaccine 

Pharmaceutical Technology

Japan’s MHLW has approved CSL and Arcturus Therapeutics’ self-amplifying mRNA (sa-mRNA) Covid-19 vaccine, ARCT-154.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

The Significance of the MHRA Approval and Upcoming FDA Review of the First Gene Editing Treatment

Worldwide Clinical Trials

By: Amy Raymond, PMP, PhD, Senior Director, Therapeutic Strategy Lead, Cellular & Genetic Medicines On November 16, the British regulatory body, Medicines and Healthcare products Regulatory Agency (MHRA) approved exagamglogene autotemcel (exa-cel) to treat severe sickle cell disease for patients ages 12 and up, becoming the first gene editing treatment to receive regulatory approval.

article thumbnail

November 29, 2023: Special Biostatistics Series Continues With Guidelines for Stepped-Wedge Trials

Rethinking Clinical Trials

In this Friday’s PCT Grand Rounds, Jim Hughes of the University of Washington will continue our special series, Advances in the Design and Analysis of Pragmatic Clinical Trials, with his presentation, “Guidelines for Design and Analysis of Stepped-Wedge Trials.” The session will be held on Friday, December 1, at 1:00 pm eastern. Hughes is a professor emeritus of biostatistics at the University of Washington.

Trials 162
article thumbnail

FDA investigating cancer risk linked to CAR-T cell therapy

Bio Pharma Dive

The agency said the benefit of approved treatments like Gilead’s Yescarta still outweighs any such risk, but the alert could slow drugmaker efforts to develop the treatments for wider use.

article thumbnail

The future of cell and gene therapy manufacturing

Pharmaceutical Technology

As more cell and gene therapies get approved to treat common conditions, scaling them up will be a challenge.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Milner Therapeutics to establish new genomics laboratory for drug discovery

Pharma Times

The new state-of-the-art facility is set to be operational in early 2024 - News - PharmaTimes

Genomics 156
article thumbnail

November 28, 2023: Workshop Summary Now Available From ‘Getting the Right Evidence to Decision-Makers Faster’

Rethinking Clinical Trials

The workshop summary is now available from the NIH Pragmatic Trials Collaboratory’s recent workshop, “Getting the Right Evidence to Decision-Makers Faster.” The 2-day workshop explored the critical cycle of evidence generation by researchers to decision-making by healthcare system leaders to implement the findings of pragmatic clinical trials conducted within healthcare systems.

article thumbnail

FDA names chief scientist Bumpus as Woodcock’s successor

Bio Pharma Dive

Bumpus, a former Johns Hopkins professor, named “creating a new model” for the FDA’s Office of Regulatory Affairs as one of her priorities when she steps into the role.

Scientist 299
article thumbnail

FDA accepts Orexo’s NDA for opioid overdose medication

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has accepted to review Orexo’s new drug application (NDA) for opioid overdose medication, OX124.

Drugs 263
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Prostate cancer focal therapy could improve costs and patient outcomes

Pharma Times

Every year, over 44,000 men are diagnosed with prostate cancer in England - News - PharmaTimes

146
146
article thumbnail

November 27, 2023: NIH Announces Funding Opportunity for Implementation Studies of Substance Use Treatment and Prevention in Populations That Experience Health Disparities

Rethinking Clinical Trials

The National Institutes of Health’s Office of Disease Prevention (ODP) issued a new funding opportunity to support implementation studies in treatment and prevention for alcohol, tobacco, and other drugs use and misuse in adult populations that experience health disparities. ODP and participating NIH Institutes and Centers are inviting applications for research projects that test innovative approaches to implementing screening, brief intervention, and referral to treatment or prevention fo

article thumbnail

BioMarin secures hemophilia gene therapy coverage in Germany

Bio Pharma Dive

Drawn-out negotiations led to a lower price than initially expected, but analysts called the agreement a step forward for the biotech company.

article thumbnail

Novovax’s Omicron-targeting Covid-19 vaccine obtains WHO emergency listing  

Pharmaceutical Technology

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Pfizer site in Connecticut in line for layoffs amid $3.5B cost-cutting campaign

Fierce Pharma

With layoffs hitting employees on both sides of the Atlantic, Pfizer’s $3.5 billion cost-cutting spree has kicked it into high gear this month. | The company's Groton, Connecticut, research site is the latest to fall victim to job cuts as part of Pfizer's massive $3.5 billion cost-cutting mission, following layoffs across the U.S. and the U.K.

Research 145
article thumbnail

November 30, 2023: HCSRN Calls for Abstracts and Panel Presentations for 2024 Annual Conference

Rethinking Clinical Trials

The Health Care Systems Research Network (HCSRN) is accepting abstract submissions and panel presentation submissions for its 2024 Annual Conference until December 11, 2023. This year’s meeting will be held in Milwaukee, Wisconsin, from April 9 to 11, 2024. The HCSRN is a 20-member research network focused on supporting research institutes aligned with healthcare delivery systems.

article thumbnail

Gilead to lay off staff at cell therapy unit Kite

Bio Pharma Dive

The cuts will impact 7% of the cancer drug division’s employees, although about 90 new roles will be created around “areas of growth.

Drugs 289
article thumbnail

FDA opens investigation into secondary cancer risk with CAR-T therapies

Pharmaceutical Technology

The agency has received reports of T-cell malignancies in patients who have previously received CAR-T cell immunotherapies.

255
255
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA investigates 'serious risk' of secondary cancer following CAR-T treatment

Fierce Pharma

In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs. | In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs.

article thumbnail

MHRA launches online eligibility checker tool via the IRP

Pharma Times

The IRP will bring life-saving medicines to UK patients from 1 January 2024 - News - PharmaTimes

Medicine 141
article thumbnail

GSK cancer drug Blenrep gets surprise trial win

Bio Pharma Dive

One year after the U.K. drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch.

Drugs 289
article thumbnail

Partnership deals for psychedelic drugs take a trip with 500% surge in 2023

Pharmaceutical Technology

Partnership deals involving psychedelic drugs saw a 500% growth in total deal volume from 2019 to 2023 year-to-date (YTD).

Drugs 246
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.